Technical Analysis for PBYI - Puma Biotechnology Inc

Grade Last Price % Change Price Change
grade F 10.55 0.67% 0.07
PBYI closed up 0.67 percent on Thursday, July 18, 2019, on 73 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Aug 7

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Down Down
See historical PBYI trend table...

Date Alert Name Type % Chg
Spinning Top Other 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 0.67%
Lower Bollinger Band Walk Weakness 0.67%
New 52 Week Low Weakness 0.67%
Below Lower BB Weakness 0.67%

Older signals for PBYI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Puma Biotechnology, Inc., a development stage biopharmaceutical company, engages in the acquisition, development, and licensing of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients and non-small cell lung cancer patients; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also involved in developing PB357, an orally administered agent, which is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Chemistry Cancer Chemical Compounds Organic Compounds Non Small Cell Lung Cancer Chloroarenes Pyridines Tyrosine Kinase Receptors Protein Kinase Inhibitor Epidermal Growth Factor Receptor Aromatic Amines Her2/Neu Advanced Breast Cancer Nitriles Treatment Of Advanced Breast Cancer Treatment Of Various Forms Of Cancer
Is PBYI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 54.2
52 Week Low 10.28
Average Volume 1,327,483
200-Day Moving Average 26.7917
50-Day Moving Average 14.5482
20-Day Moving Average 12.2535
10-Day Moving Average 11.527
Average True Range 0.684
ADX 53.34
+DI 10.379
-DI 36.5699
Chandelier Exit (Long, 3 ATRs ) 12.608
Chandelier Exit (Short, 3 ATRs ) 12.332
Upper Bollinger Band 14.126
Lower Bollinger Band 10.381
Percent B (%b) 0.05
BandWidth 30.562696
MACD Line -1.2995
MACD Signal Line -1.3597
MACD Histogram 0.0602
Fundamentals Value
Market Cap 392.52 Million
Num Shares 37.2 Million
EPS -8.14
Price-to-Earnings (P/E) Ratio -1.30
Price-to-Sales 0.00
Price-to-Book 37.58
PEG Ratio 0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.23
Resistance 3 (R3) 11.21 10.97 11.11
Resistance 2 (R2) 10.97 10.80 10.98 11.07
Resistance 1 (R1) 10.76 10.69 10.87 10.78 11.04
Pivot Point 10.52 10.52 10.57 10.53 10.52
Support 1 (S1) 10.31 10.35 10.42 10.33 10.06
Support 2 (S2) 10.07 10.24 10.08 10.03
Support 3 (S3) 9.86 10.07 9.99
Support 4 (S4) 9.88